Apellis Pharmaceuticals, Inc. (APLS)
NASDAQ: APLS · IEX Real-Time Price · USD
49.93
+1.21 (2.48%)
At close: Apr 24, 2024, 4:00 PM
48.99
-0.94 (-1.88%)
After-hours: Apr 24, 2024, 7:13 PM EDT
Apellis Pharmaceuticals Stock Forecast
Stock Price Forecast
The 17 analysts with 12-month price forecasts for APLS stock have an average target of 76.24, with a low estimate of 46 and a high estimate of 106. The average target predicts an increase of 52.69% from the current stock price of 49.93.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for APLS stock from 17 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 8 | 9 | 9 | 10 | 10 | 9 |
| Buy | 4 | 3 | 3 | 3 | 3 | 3 |
| Hold | 5 | 5 | 5 | 5 | 5 | 5 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 17 | 17 | 17 | 18 | 18 | 17 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wedbush | Wedbush | Hold Maintains $67 → $57 | Hold | Maintains | $67 → $57 | +14.16% | Apr 17, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $92 | Strong Buy | Reiterates | $92 | +84.26% | Apr 15, 2024 |
| Needham | Needham | Strong Buy Reiterates $85 | Strong Buy | Reiterates | $85 | +70.24% | Apr 9, 2024 |
| Mizuho | Mizuho | Hold Maintains $60 | Hold | Maintains | $60 | +20.17% | Mar 27, 2024 |
| JP Morgan | JP Morgan | Buy Maintains $78 → $79 | Buy | Maintains | $78 → $79 | +58.22% | Mar 6, 2024 |
Financial Forecast
Revenue This Year
812.77M
from 396.59M
Increased by 104.94%
Revenue Next Year
1.21B
from 812.77M
Increased by 48.38%
EPS This Year
-1.23
from -4.45
EPS Next Year
1.23
from -1.23
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 965.8M | 1.6B | 2.2B | 2.2B | 2.6B |
| Avg | 812.8M | 1.2B | 1.6B | 1.8B | 2.2B |
| Low | 698.7M | 927.1M | 1.3B | 1.1B | 1.2B |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 143.5% | 102.6% | 79.4% | 32.3% | 45.4% |
| Avg | 104.9% | 48.4% | 36.2% | 8.3% | 22.9% |
| Low | 76.2% | 14.1% | 4.2% | -35.1% | -31.1% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 0.48 | 2.39 | 7.06 | 6.47 | 8.27 |
| Avg | -1.23 | 1.23 | 3.91 | 5.01 | 6.92 |
| Low | -2.19 | 0.13 | 2.21 | 3.57 | 4.62 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | 473.9% | 65.5% | 65.3% |
| Avg | - | - | 217.9% | 28.1% | 38.2% |
| Low | - | - | 80.1% | -8.7% | -7.8% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.